GI
Therapeutic Areas
Resolve Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RSLV-132 | Sjögren's Disease | Phase 2 |
| RSLV-132 / Platform | Polytrauma / SIRS | Observational Study |
Leadership Team at Resolve Therapeutics
JP
James Posada, Ph.D.
Founder, Chief Executive Officer
PK
Peter Kiener, Ph.D.
Chairman of the Board of Managers